Prometrium Max Dose: How High Can You Go and Why It Matters

What Is Prometrium and Why Does the Dose Matter for Women?

Prometrium is oral micronized progesterone, the bioidentical form of the progesterone your ovaries produce. Unlike synthetic progestins such as medroxyprogesterone acetate (MPA), micronized progesterone has a receptor-binding profile that more closely mirrors endogenous progesterone, which changes how it affects breast tissue, mood, and sleep. The dose you take determines how much of that activity you actually get, and because progesterone metabolism differs between women, the "right" dose is not universal.

The FDA-approved prescribing information for Prometrium lists two distinct approved indications with different dose ceilings. Understanding where those ceilings come from, and when a clinician might go beyond them, requires understanding your hormonal context, your life stage, and the real evidence behind each dose level.

The Two FDA-Approved Indications

Endometrial protection in postmenopausal women on estrogen: 200 mg orally at bedtime for 12 consecutive days of a 28-day cycle. This cyclic schedule mimics a withdrawal bleed and protects the uterine lining from unopposed estrogen-driven proliferation.

Secondary amenorrhea: 400 mg orally at bedtime for 10 days. This higher, shorter course triggers a progesterone-withdrawal bleed to confirm the uterus can respond.

These two doses, 200 mg and 400 mg, define the FDA-studied range. Everything above 200 mg in a continuous or extended regimen is off-label.

How Progesterone Is Processed Differently in Women

Micronized progesterone is extensively metabolized on first pass through the liver. Oral bioavailability is low, roughly 10%, because of this first-pass effect, which is why doses must be higher than the nanogram-per-milliliter serum levels would suggest. When you eat a meal, especially a fatty one, peak serum progesterone rises two to three times compared to fasting administration. This food-fat interaction means your effective dose can swing substantially based on when and what you eat.

Hormonal Status Changes Everything

Your progesterone metabolism shifts across life stages in ways that directly affect how a given dose behaves:

• Reproductive years: Your corpus luteum produces 25 to 50 mg of progesterone daily in the luteal phase. Exogenous oral progesterone at 200 mg sits far above that endogenous output, which is why sedation is common.
• Perimenopause: Progesterone production becomes erratic. You may have cycles where you produce almost no progesterone (anovulatory cycles) and others where production is near normal. This variability makes steady-dose oral progesterone harder to calibrate and may explain why some women need dose increases mid-titration.
• Postmenopause: Endogenous progesterone is essentially zero. The entire progesterone burden comes from the prescription. Dose requirements for endometrial protection are well-established here, and the PEPI trial remains the foundational evidence.

The PEPI Trial and What It Actually Showed

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial published in JAMA in 1995 randomized 875 postmenopausal women across five hormone regimens, including a micronized progesterone arm at 200 mg cyclically. After three years, the cyclic micronized progesterone arm showed the most favorable HDL-cholesterol profile of all the progestogen regimens and achieved adequate endometrial protection in the majority of participants. The PEPI data established 200 mg cyclic as the benchmark dose for endometrial safety in HRT. What PEPI did not study was higher continuous doses, so the 300-400 mg continuous range used in some clinical practices rests on observational and pharmacokinetic data, not a powered RCT.

Standard Titration: Starting Low and Moving Up

Most clinicians start Prometrium at the lowest effective dose for the indication, then adjust based on symptom control, tolerability, and, where appropriate, serum progesterone levels. The standard titration ladder looks like this:

Tier 1: 100 mg Nightly (Off-Label Starting Dose)

Some prescribers begin postmenopausal women on continuous combined HRT at 100 mg nightly rather than the FDA-approved 200 mg cyclic schedule. The rationale is that continuous low-dose progesterone may suppress endometrial proliferation adequately in women using low-dose estrogen. Evidence supporting 100 mg continuous comes largely from the KEEPS trial, which used 200 mg cyclic as the comparator and observed acceptable endometrial outcomes. Off-label 100 mg continuous is common in practice but carries the caveat that endometrial biopsy surveillance becomes more important.

Tier 2: 200 mg Nightly (FDA-Approved Anchor Dose)

This is the dose with the most evidence. Taken at bedtime, 200 mg oral micronized progesterone achieves peak serum levels of approximately 17 ng/mL at two to three hours post-dose, then falls rapidly. By morning, serum progesterone is near baseline. This profile explains the bedtime-only dosing convention: the sedation hits during sleep, and daytime function is largely unaffected for most women.

Symptoms that 200 mg typically addresses include perimenopausal insomnia, night sweats that have not resolved on estrogen alone, and endometrial protection in standard-dose estrogen users.

Tier 3: 300 mg Nightly (Off-Label Step-Up)

When 200 mg fails to control symptoms, particularly breakthrough bleeding in women on estrogen, or when a woman's uterine lining continues to thicken on endometrial ultrasound, some clinicians step to 300 mg. This increase is empirical. There is no RCT comparing 200 mg to 300 mg on endometrial outcomes. The dose is sometimes split as 200 mg at bedtime plus 100 mg in the early evening to reduce peak sedation, though splitting reduces the sleep-benefit effect that many women value.

Tier 4: 400 mg Nightly (FDA-Approved Ceiling, Off-Label Duration)

The FDA label allows 400 mg for 10 days to induce withdrawal bleeding in secondary amenorrhea. Using 400 mg continuously or cyclically over months for menopause management or PMDD is off-label. At 400 mg, sedation is marked. Falls in older women are a real concern. Some high-dose users describe a strong anxiolytic and sleep-consolidating effect that they consider therapeutic, but this must be weighed against next-day cognitive fogginess, which is more common above 300 mg.

When and Why Clinicians Go Beyond 200 mg

The WomanRx Progesterone Tier Decision Framework identifies four clinical scenarios where a prescriber might consider dose escalation above 200 mg, and what evidence (or lack thereof) supports each move:

| Clinical Scenario | Starting Dose | Step-Up Rationale | Evidence Level | |---|---|---|---| | Persistent endometrial thickening on standard HRT | 200 mg cyclic | Insufficient progestogenic exposure; step to 300 mg continuous or increase cyclic days | Observational, expert consensus | | Breakthrough uterine bleeding on continuous combined HRT | 200 mg nightly | Poor suppression; consider 300 mg or switch to IUD | Case series, clinical experience | | Perimenopausal insomnia refractory to 200 mg | 200 mg bedtime | GABAergic metabolite (allopregnanolone) dose-response; 300 mg may deepen sleep | Pharmacokinetic data, small RCTs | | PMDD or premenstrual exacerbation of mood disorder | 100-200 mg luteal phase | Off-label; mixed evidence; some women report benefit | Limited RCT data, case series |

Prometrium Across Life Stages

Reproductive Years (Ages 18-40)

In cycling women, Prometrium is most commonly used for luteal-phase support, secondary amenorrhea diagnosis, or off-label PMDD management. The 400 mg, 10-day course for secondary amenorrhea is FDA-approved and appropriate here. Women using Prometrium luteal-phase support while trying to conceive should discuss the distinction between oral and vaginal micronized progesterone: vaginal delivery achieves higher local uterine concentrations than oral delivery at equivalent doses, which is why ASRM guidelines for luteal-phase support in ART prefer vaginal progesterone.

Perimenopause (Typically Ages 40-51)

This is where dose calibration becomes most complex. Anovulatory cycles mean erratic endogenous progesterone, irregular bleeding, and unpredictable estrogen exposure. Many perimenopausal women start Prometrium for cycle regulation or sleep, then find that as menopause approaches and they add systemic estrogen, the progesterone dose needs re-evaluation. Starting at 100 mg and titrating up based on bleeding pattern and symptom response is a reasonable approach during this transition.

Postmenopause

The evidence base is strongest here. Any postmenopausal woman with a uterus who uses systemic estrogen requires adequate progestogen to protect the endometrium. The Menopause Society (formerly NAMS) position statement supports micronized progesterone as the preferred progestogen for women with concerns about breast cancer risk, based on observational data suggesting a more favorable breast-tissue profile than synthetic progestins. The dose and schedule (cyclic versus continuous) should be guided by symptom pattern and endometrial monitoring.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Prometrium's FDA label carries a warning that it is not indicated for use as a contraceptive or infertility treatment and that peanut oil (present in the capsule formulation) may cause allergic reactions. More critically, the FDA label notes that Prometrium should not be used in pregnant women for indications other than those specifically approved, and it is not approved to prevent miscarriage.

The PRISM trial, published in the New England Journal of Medicine in 2019, examined vaginal micronized progesterone (not oral Prometrium) in women with early pregnancy bleeding and a history of miscarriage. It found a modest benefit in a subgroup analysis. Oral micronized progesterone does not have equivalent uterine-tissue delivery to vaginal formulations and should not be substituted for vaginal progesterone in luteal support or threatened miscarriage protocols.

If you are pregnant or planning pregnancy and a provider has prescribed Prometrium orally, ask specifically whether vaginal micronized progesterone (Endometrin, Crinone, or compounded vaginal suppositories) would be more appropriate for your situation.

Prometrium capsules contain peanut oil. Women with peanut allergy must not use this formulation. Compounded micronized progesterone in a peanut-free base is an alternative.

Lactation

Progesterone is present in breast milk in small amounts. Published pharmacokinetic data show that endogenous progesterone transfers into human milk, with milk-to-plasma ratios below 1.0, though controlled lactation data specific to oral micronized progesterone at therapeutic doses are limited. The clinical significance for a nursing infant is not established. Women who are breastfeeding and considering progesterone therapy should discuss the balance of risks and benefits with their provider; the general consensus is that low-dose progestogen-only contraception is compatible with lactation, but therapeutic HRT doses have less data.

Contraception Requirement

Prometrium at any dose does not reliably suppress ovulation. Perimenopausal women who still have cycles and use Prometrium for symptom management must use effective contraception if they do not wish to become pregnant. This is a common oversight. A woman in her mid-40s having irregular cycles may assume she cannot get pregnant; ACOG advises continuing contraception until 12 months after the final menstrual period in women who reach menopause after age 50.

Who This Is Right For and Who Should Pause

Good Candidates for Dose Escalation

• Postmenopausal women on systemic estrogen whose endometrial lining remains thickened above 4-5 mm on standard 200 mg cyclic dosing
• Perimenopausal women with documented anovulatory cycles and refractory insomnia who tolerate 200 mg without residual sedation
• Women with a history of endometrial hyperplasia requiring more aggressive progestogenic suppression
• Women who have tried synthetic progestins and experienced intolerable mood side effects, since micronized progesterone's neutral or anxiolytic mood profile is better documented

Women Who Should Approach Escalation Cautiously

• Women over 65 where fall risk from sedation at 300-400 mg is clinically significant
• Women with hepatic impairment, since first-pass metabolism may be reduced and effective dose may be higher than expected
• Women with depression or a history of adverse mood reactions to progesterone
• Women with peanut allergy (must use compounded formulation)
• Women seeking pregnancy support who should be directed to vaginal progesterone instead

Monitoring While on Prometrium

Dose escalation should not happen in a vacuum. Monitoring during titration includes:

Endometrial Surveillance

Any woman using off-label higher-dose or extended-duration Prometrium should have a baseline transvaginal ultrasound to document endometrial thickness, then annual follow-up. Endometrial thickness above 4 mm in a postmenopausal woman on HRT warrants further evaluation regardless of the progesterone dose.

Serum Progesterone Levels

Serum progesterone drawn the morning after a 200 mg or 400 mg dose reflects trough levels, not peak levels, and is a poor surrogate for endometrial tissue exposure. Serum monitoring is not required by guidelines but may help identify extreme non-responders or women with unusually fast metabolism who may need a higher dose.

Symptom Tracking

A structured symptom log, tracking bleeding pattern, sleep quality, next-day sedation, and mood, gives the clinician actionable data between appointments. If you are titrating, keep a daily log for at least six weeks at each dose level before concluding whether it works.

Comparing Oral Versus Vaginal Micronized Progesterone at High Doses

Many women and even some clinicians conflate oral and vaginal micronized progesterone. They are the same molecule but behave differently pharmacologically. Vaginal progesterone achieves a uterine-to-serum concentration ratio of 10 to 40 times higher than oral administration because of a "first uterine pass" effect through the vaginal-uterine venous plexus. This means a vaginal dose of 100 mg may protect the endometrium as effectively as a much higher oral dose, while producing far lower serum levels and less systemic (sedative) effect.

For women whose main indication is endometrial protection and who find oral progesterone sedation intolerable even at 100 mg, switching to vaginal micronized progesterone rather than escalating the oral dose is a legitimate strategy.

What the Evidence Gap Means for You

Women have been under-represented in pharmacokinetic research on progesterone for decades. The PEPI trial, conducted in the early 1990s, remains the primary controlled evidence for oral micronized progesterone in menopause management. No adequately powered RCT has compared 200 mg to 300 mg or 400 mg continuous oral progesterone on endometrial outcomes, cardiovascular biomarkers, or breast-tissue effects. The dose ranges used above 200 mg in clinical practice rest on pharmacokinetic reasoning, smaller observational studies, and expert consensus, not head-to-head trial data.

This matters for shared decision-making. When your clinician recommends a dose above 200 mg, you have the right to know that the evidence is extrapolated, not directly established in a controlled trial. The benefit-risk calculation is still often favorable, but it should be made explicitly, not assumed.